CLINICAL EVALUATION OF CB 1348 IN MALIGNANT LYMPHOMA AND RELATED DISEASES
- 1 April 1958
- journal article
- research article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 68 (3) , 915-925
- https://doi.org/10.1111/j.1749-6632.1958.tb42649.x
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- CHLORAMBUCIL IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA AND CERTAIN LYMPHOMASJAMA, 1956
- Evaluation of CB 1348 in Hodgkin's Disease and Allied DisordersArchives of internal medicine (1960), 1956
- Early experience withp-(N,N-di-2-chloroethyl)-aminophenylbutyric acid (CB 1348), a new chemotherapeutic agent effective in the treatment of chronic lymphocytic leukemiaCancer, 1956
- Clinical Trials of p-(Di-2-chloroethylamine)-phenylbutyric Acid (CB 1348) in Malignant LymphomaBMJ, 1955
- A Comparison of the Effects of Radiation and Radiomimetic Chemicals on the BloodBritish Journal of Haematology, 1955
- 486. Aryl-2-halogenoalkylamines. Part XII. Some carboxylic derivatives of NN-di-2-chloroethylanilineJournal of the Chemical Society, 1953